Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selectively augment tumor antigen-specific CD8(+) T-cell re...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yuexin, Miller, Chris P., Warren, Edus H., Tykodi, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189101/
https://www.ncbi.nlm.nih.gov/pubmed/33667140
http://dx.doi.org/10.1080/21645515.2020.1870846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189101/
https://www.ncbi.nlm.nih.gov/pubmed/33667140
http://dx.doi.org/10.1080/21645515.2020.1870846

Ejemplares similares